5 results about "Routine laboratory" patented technology

This invention provides a negative pressure isolation live microscope experimental box. The experimental box, through its closed negative pressure design, ensures the biosafety of experiments with pathogens of BSL-2 level and above, meeting the requirements of the safety committee review. At the same time, its innovative box-type integrated window structure eliminates the vibration torque caused by animal movement in traditional suspended windows from a mechanical design perspective, providing unparalleled stability for high-precision imaging. Ultimately, it makes it possible to safely and stably conduct live microscopic studies of highly pathogenic infection models in a conventional laboratory.

This invention discloses an optimization method and system for a predictive model of diabetic complications. It involves collecting routine laboratory test data from diabetic patients, performing preprocessing such as missing value removal, label merging, and SMOTE resampling to construct a balanced dataset. The average importance of indicators is evaluated using multiple machine learning models to select a subset of key features. Random forest, XGBoost, support vector machine, and multilayer perceptron are selected as base classifiers, and after hyperparameter optimization, a stacked ensemble learning model is constructed to further improve predictive performance. Finally, the model is packaged as an API service and embedded into a hospital information system to achieve high-precision, low-cost, and real-time risk prediction of diabetic complications. Experimental results show that this invention achieves an accuracy of 98.5% and an AUC of 99.76% in predicting diabetic nephropathy complications, outperforming single models.

Predicting treatment benefits of immune checkpoint inhibitor drugs (ICIs) without resorting to advanced genomic or immunologic assays is a major unmet clinical need. This disclosure provides a predictive model using machine-learning approaches based on routine laboratory test results in clinical practice.

The application discloses a novel autoantibody combination for idiopathic retroperitoneal fibrosis and diagnostic and monitoring applications thereof. The application screens and verifies five iRPF-specific autoantibodies, including anti-RBPJ antibody, anti-TPM1 antibody, anti-C1D antibody, anti-NPM1 antibody, anti-IL-1A antibody, and IgG4 subtypes of the above antibodies; the autoantibodies are significantly increased in iRPF patients and have a medium and above ability to identify iRPF, wherein the anti-C1D antibody can effectively distinguish iRPF from RPS; and the anti-TPM1, NPM1 and RBPJ antibodies can also be used for disease activity monitoring. The screened autoantibodies directly reflect the autoimmune nature of iRPF, have higher specificity than existing laboratory indicators, can be detected by conventional laboratory equipment, have low cost and good promotion, and have good clinical application prospects.

The application relates to application of CTRP4 in condition assessment and treatment of herpes simplex encephalitis, belongs to the technical field of biological medicine, and solves one of the problems that the condition assessment of HSE in the prior art is highly subjective, an imaging examination cannot reflect intracranial core lesions in real time and dynamically, is not related to a core biological mechanism of a disease, brain tissue samples are difficult to obtain, direct and effective indexes of intracranial disease states are scarce, and routine laboratory examinations are not specific for central nervous system pathologies and recovery of nerve functions. The application comprises application of CTRP4 in preparation of a herpes simplex encephalitis diagnostic reagent, and the diagnostic reagent is used for detecting the expression level of CTRP4 in a biological sample of a subject. The application of CTRP4 in preparation of the herpes simplex encephalitis diagnostic reagent can provide a highly specific, non-invasive and dynamic herpes simplex encephalitis condition assessment scheme, and solves the limitation problem of subjective diagnosis by doctors in traditional assessment.